Pricing Log in Create free account
Saturday 17 October 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.

790.74 5.60 −0.70%
Market cap
$82.0B
P/E
18.9×
Fwd P/E
16.5×
Dividend yield
0.47%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Regeneron Pharmaceuticals, Inc. (REGN) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at a EV/EBITDA of 17.6×. Over the past ten years it has ranged from 5.9× (June 2022) to 56.4× (June 2015); the current reading is higher than 54% of that period. That is above the Biotechnology industry median of 0.6× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 18.5× 15.00%
FY2024 16.1× (19.97%)
FY2023 20.1× 38.87%
FY2022 14.5× 107.32%
FY2021 7.0× (49.33%)
FY2020 13.8× (13.29%)
FY2019 15.9× 11.73%
FY2018 14.2× (20.72%)
FY2017 18.0× (34.01%)
FY2016 27.2× (34.66%)

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 13.6× (24.31%)
Mar 2026 18.0× (2.76%)
Dec 2025 18.5× 44.48%
Sep 2025 12.8× 7.45%
42 more quarters

Against its own ten years

Low 5.9× High 56.4×
Ten-year median 16.9×
Current reading's percentile 54

EV/EBITDA against peers

Company EV/EBITDA
ROIV Roivant Sciences Ltd. compare n/m
MRNA Moderna, Inc. compare n/m
RVMD Revolution Medicines, Inc. compare n/m
REGN Regeneron Pharmaceuticals, Inc. 17.6×
RPRX Royalty Pharma PLC compare 22.9×
VRTX Vertex Pharmaceuticals Incorporated compare 23.9×
ALNY Alnylam Pharmaceuticals, Inc. compare 27.2×
ARGX argenex SE compare 29.6×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 34.6×
Biotechnology industry median 0.6×
Healthcare sector median 9.2×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on REGN